New obesity shot tested in teens: safe or not?
NCT ID NCT07559136
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of an investigational injection called HRS9531 in 48 Chinese adolescents aged 12 to 17 who are obese. Participants receive either the drug or a placebo, and researchers monitor side effects, drug levels in the blood, and changes in weight and waist size. The study requires participants to have maintained a stable diet and exercise routine for at least 12 weeks before joining.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?